Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas.
Sophie SchneiderThomas FerteOcéane DucharmeLéa DoussetSorilla PreyCaroline DutriauxEmilie GerardMarie Beylot-BarryAnne Pham-LedardPublished in: Journal of cancer research and clinical oncology (2024)
Patients with acSCC are usually very frail and elderly. OS increased over time, with a twofold improvement between periods 1 and 2, whereas progression-free survival (PFS) did not increase. Access to immunotherapy reduced mortality in a majority of patients in period 2. Immunosuppression and advanced age were associated with lower PFS.
Keyphrases
- free survival
- squamous cell
- locally advanced
- end stage renal disease
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- chronic kidney disease
- small cell lung cancer
- rectal cancer
- neoadjuvant chemotherapy
- cardiovascular events
- high grade
- peritoneal dialysis
- prognostic factors
- type diabetes
- middle aged
- cardiovascular disease
- patient reported outcomes
- phase ii study
- double blind